Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

Werewolf Therapeutics to present company overview at Jefferies Healthcare Conference

Positive

• Werewolf Therapeutics, Inc. will present a company overview at the Jefferies Healthcare Conference on June 8. The presentation will focus on the development of conditionally activated therapeutics for cancer treatment. A live webcast will be available for viewing, and an archived replay will be accessible for 90 days.

Negative

• None.

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7^th-9^th, 2023, in New York, NY.

A link to the live webcast of the presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.

About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. To learn more visit www.werewolftx.com.

Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
Josh.Rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

When and where will Werewolf Therapeutics present a company overview?

Werewolf Therapeutics will present a company overview at the Jefferies Healthcare Conference on June 8 in New York, NY.

What is the focus of Werewolf Therapeutics' presentation?

The presentation will focus on the development of conditionally activated therapeutics for the treatment of cancer.

How can I watch the presentation?

A live webcast of the presentation will be available at https://investors.werewolftx.com/news-and-events/events.

Will there be a replay of the presentation?

Yes, an archived replay will be available for approximately 90 days following the event.